Analyzing e.l.f. Beauty (NYSE:ELF) and Dermata Therapeutics (NASDAQ:DRMAW)

e.l.f. Beauty (NYSE:ELF) and Dermata Therapeutics (NASDAQ:DRMAW) are both consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

This table compares e.l.f. Beauty and Dermata Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
e.l.f. Beauty	$1.64 billion	3.93	$26.32 million	$1.00	109.04
Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A

e.l.f. Beauty has higher revenue and earnings than Dermata Therapeutics.

Profitability

This table compares e.l.f. Beauty and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
e.l.f. Beauty	3.38%	14.07%	6.81%
Dermata Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and target prices for e.l.f. Beauty and Dermata Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
e.l.f. Beauty	1	5	10	2	2.72
Dermata Therapeutics	0	0	0	0	0.00

e.l.f. Beauty presently has a consensus target price of $92.12, suggesting a potential downside of 15.51%. Given e.l.f. Beauty’s stronger consensus rating and higher probable upside, analysts plainly believe e.l.f. Beauty is more favorable than Dermata Therapeutics.

Institutional and Insider Ownership

92.4% of e.l.f. Beauty shares are owned by institutional investors. 3.5% of e.l.f. Beauty shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

e.l.f. Beauty beats Dermata Therapeutics on 10 of the 10 factors compared between the two stocks.

About e.l.f. Beauty

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, WELL People and KEYS soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.